Abstract Library

#4619 Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study

Introduction: Radioligand therapy with lutetium-177 labelled somatostatin receptor (SSTR) agonists (177Lu-DOTATATE or 177Lu-DOTATOC) showed limited response rate and durability. The novel SSTR antagonist DOTA-LM3 labelled with terbium-161, which co-emits conversion and Auger electrons in addition to β- particles, potentially increasing tumour doses and offering a more effective treatment for micro metastases.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Westerbergh F, McDougall L, Christ E, Nicolas G,

Keywords: Radionuclide therapy, PRRT, Auger electrons, Conversion electrons, Terbium-161, radiolabelled somatostatin antagonist, neuroendocrine tumour,

#4454 Impact of pathological review of neuroendocrine neoplasms (NENs) within the French national ENDOCAN/TENpath network

Introduction: NENs are rare tumours which can benefit from specialised pathological assessment. In France, the ENDOCAN/TENpath network, composed of 33 expert pathologists in 20 centres, provides consultations (2nd readings) at the request of non-specialist pathologists. Challenging cases are reviewed in monthly virtual meetings grouping all expert pathologists (third readings).

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Scoazec J, Bani M, Boulagnon-Rombi C, Poté N,

Keywords: NEN, Pathology, Review, Neuroendocrine Neoplasm,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#3845 The lungNENomics project – A comprehensive multidisciplinary characterisation of pulmonary carcinoids

Introduction: Lung neuroendocrine tumors (LNETs) are subdivided into low-grade (typical) and intermediate-grade (atypical) carcinoids, at higher risk of developing metastases. We have previously identified 3 LNETs molecular groups with different prognoses, as well as “supra-carcinoids” with molecular profiles of higher-grade neuroendocrine carcinomas. Despite promising results, there is still no consensus on their differential diagnosis and treatment and little is known about how some tumors evolve toward more aggressive phenotypes.

Conference:

Presenting Author:

Authors: Foll M, Sexton-Oates A, Mathian E, Alcala N, Mangiante L,

Keywords: lung carcinoid, deep learning, genomic, evolution, multi-omics, spatial analyses,

#3835 Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine cancer

Introduction: 28% of low-grade neuroendocrine tumors (NETs) present at advanced stages and are unresponsive to therapy, pointing to a gap in our understanding of how these tumors arise and progress.

Conference:

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Moonen L, den Hartigh L, Mangiante L,

Keywords: Organoids, LCNEC, NET, pulmonary carcinoid, EGF,